This study aimed to clarify the significance of therapeutic timing on the effectiveness of nivolumab for treating metastatic renal cell carcinoma.
Fifty-eight patients with metastatic renal cell carcinoma treated with nivolumab monotherapy were retrospectively studied. Patients who were treated with nivolumab as second-line therapy were included in the second-line group, while the others were included in the later-line group. The clinicopathological characteristics, effects of nivolumab, and prognoses of these groups were compared.
Twenty and thirty-eight patients were included in the second-line and later-line groups, respectively. There were no significant differences in the distribution of International Metastatic Renal Cell Carcinoma Database Consotium risk and other clinicopathological characteristics between the 2 groups. The proportion of patients whose objective best response was progressive disease in the second-line group was significantly lower than that in the later-line group (15% vs. 50%, p = 0.0090). The 50% progression-free survival with nivolumab in the second-line group was significantly better than that in the later-line group (not reached and 5 months, p = 0.0018). Multivariate analysis showed that the second-line setting was an independent predictive factor for better progression-free survival (p = 0.0028, hazard ratio = 0.108). The 50% overall survival after starting nivolumab in the second-line and later-line groups was not reached and 27.8 months, respectively (p = 0.2652).
The therapeutic efficacy of nivolumab as second-line therapy is expected to be better than that of later therapy.
Current urology. 2022 Aug 02 [Epub]
Jun Teishima, Daiki Murata, Kazuma Yukihiro, Yohei Sekino, Shogo Inoue, Tetsutaro Hayashi, Koji Mita, Yasuhisa Hasegawa, Masao Kato, Mitsuru Kajiwara, Masanobu Shigeta, Satoshi Maruyama, Hiroyuki Moriyama, Seiji Fujiwara, Akio Matsubara
Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan., Department of Urology, Hiroshima-City Asa Citizens Hospital, Hiroshima, Japan., Department of Urology, Fukuyama Medical Center, Fukuyama, Japan., Department of Urology, Hiroshima General Hospital, Hatsukaichi, Japan., Department of Urology, Hiroshima Prefectural Hospital, Hiroshima, Japan., Department of Urology, Kure Medical Center and Chugoku Cancer Center, Kure, Japan., Department of Urology, Miyoshi Central Hospital, Miyoshi, Japan., Department of Urology, Onomichi General Hospital, Onomichi, Japan., Department of Urology, Higashi-Hiroshima Medical Center, Higashi-Hiroshima, Japan.